Guidelines and regulation at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

5 organizations at EBF 2026 present work in guidelines and regulation (ICH M10 and beyond): 4 CROs and suppliers and 1 drug developer. Between them they bring 13 presentations to the program. Most represented: Roche (9 on the program), Celerion (2 on the program), Mercodia (1 on the program). 5 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–5 of 5 organizations

Organization	EBF 2026 Attendance
Roche Basel, Switzerland
roche.com Pharma Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.	Talk Tue Nov 17 11:30–11:50am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt Automation & AI · Ligand binding Talk Tue Nov 17 2:40–3pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches New modalities · LC–MS Talk Tue Nov 17 5:20–5:40pm Part of Session 7: BM CoU in practice Navigating Soluble Biomarker Complexity: Challenges, Assay Strategy, and Case Studies Biomarkers Talk Wed Nov 18 9–9:20am Part of Session 10: Bioanalysis Beyond Conventional Matrices From First-in-Human to Multi-Site Trials: Practical Bioanalytical Strategies to Preserve CSF Pharmacokinetic Data for Highly Adsorptive Molecules Sampling Talk Wed Nov 18 9:20–9:40am Part of Session 12: Assay life cycle Assay Lifecycle in Practice: Strategic Stewardship, Change Control, and Revalidation Case Studies Regulation Talk Wed Nov 18 9:40–10am Part of Session 10: Bioanalysis Beyond Conventional Matrices Operationalizing Unstable Biomarkers: How Biosample Operations and Bioanalysis Enable Successful Scale-Up from Single-Site to Multi-Site Clinical Trials Biomarkers · Sampling Talk Wed Nov 18 5–5:20pm Part of Workshop 10: ADA - Adaptive Tier Overcoming the 3-Tier ADA Testing Paradigm via Mechanistic Assay Understanding Immunogenicity Talk Thu Nov 19 9:20–9:40am Part of Session 16: Protein MS tech 1 A Multiplexed LC-MS/MS Strategy for the Simultaneous Quantification of a Transgene Protein and its Endogenous Counterpart in a Gene Therapy Program. LC–MS Talk Thu Nov 19 11:30–11:50am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Navigating High-Plex Profiling and Targeted Quantification in Drug Development Biomarkers
Celerion Lincoln, Nebraska	◇Sponsor
celerion.com Bioanalytical CROsSponsor Clinical research organization running early-phase clinical pharmacology studies and regulated bioanalysis.	Talk Wed Nov 18 10–10:20am Part of Session 12: Assay life cycle Beyond Reagent Continuity: A Strategic Approach to Assay Life Cycle Management and Method Evolution Regulation Talk Wed Nov 18 12:40–1pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 PABAD in Action: Advancing Drug-Tolerant NAb Testing Immunogenicity
Mercodia Uppsala, Sweden	◇Sponsor
mercodia.com Instruments, reagents & softwareSponsor Makes immunoassay kits for metabolic and other biomarkers and runs bioanalytical assay services.	Talk Wed Nov 18 10:20–10:40am Part of Session 12: Assay life cycle Lifecycle Management of a Clinical PK Assay Through Change Control, Investigation, Optimization and Revalidation Ligand binding · Regulation
up to data Wörrstadt, Germany	◇Sponsor
uptodata.com Instruments, reagents & softwareSponsor Lab-informatics firm that implements LIMS and study-data software for regulated laboratories.	Talk Wed Nov 18 11:50am–12:10pm Part of Workshop 2: Emerging challenges in the e-environment Generative AI in Regulated Bioanalytical Reporting: A Two-Layer Validation Architecture for GxP-Compliant Deployment Automation & AI · Regulation
Alchemi	◇Sponsor
alchemi.bio Instruments, reagents & softwareSponsor AI platform whose agents draft and review regulated drug-development documents, such as study reports, for pharma, biotech and CRO teams.	Sponsor In the meeting’s sponsor directory, with no session on the public program